DALLAS, June 26, 2012 /PRNewswire/ -- Goldfarb LLP is investigating whether the board of directors of Aeterna Zentaris, Inc. (NASDAQ: AEZS) violated shareholder protection laws for issuing materially false and misleading statements to investors that artificially inflated the company's stock price. Concerned Aeterna Zentaris investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or [email protected] about their rights and remedies.
"On April 2, 2012, the company announced that its development-stage colon cancer drug, perifosine, failed to improve overall survival in patients in testing," securities lawyer Hamilton Lindley said. "As a result, shares have fallen from $2.14 per share on March 30 to $0.73 per share on April 2, losing approximately 66% of their value. Our proposed shareholder lawsuit will seek to ensure that proper controls are placed to ensure accurate financial reporting, to correct any improper behavior, and to improve the company's value for investors."
Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Aeterna Zentaris, Inc. shareholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at
[email protected] or 877-583-2855.
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
SOURCE Goldfarb LLP